HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by the U.S.
INTRODUCTION
Current highly active antiretroviral therapy (HAART) against HIV infection has, until recently, typically consisted of two reverse transcriptase inhibitors and a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI) for treatmentnaïve adults [1] . HIV drug resistance threatens the long-term efficacy of HAART in both developed and developing country settings (reviewed in [2] [3] [4] ) and this has led to the development of a new class of drugs termed integrase inhibitors. As is the case for all antiretroviral drugs, HIV has the ability to acquire resistance against integrase inhibitors and this occurs through discrete mutations in the integrase coding sequence (reviewed in [5] [6] [7] [8] ). These mutations can be analyzed according to several genotyping resistance interpretation algorithms.
The issue of whether various integrase inhibitors may be used sequentially, i.e., in a sequential strategy, is a subject of great potential importance. Indeed, this concept has been studied from the beginnings of the field of antiretroviral therapy to develop strategies that might enable patients to benefit from newer classes of drugs, even if they had previously failed therapy while on older compounds against which resistance had developed [3] . In some cases, newer compounds could be used even within single drug classes to provide patient benefit in the event of resistance. A good example of this has been the use of ritonavir-boosted darunavir (DRV) that has a high genetic barrier for resistance for use in the place of earlier protease inhibitors such as nelfinavir (NFV) and ritonavir-boosted lopinavir (LPV) that have lower genetic barriers to resistance [9] [10] [11] [12] . Due to the fact that ritonavir helps to maintain higher levels of PIs in the blood and tissues of treated individuals, the action of these compounds is prolonged and their genetic barrier for resistance is increased.
It has also long been established that members of different drug families may be used even if resistance has developed against members of other drug classes. As an example, the development of drug resistance to the NNRTI family of compounds can often be confronted through the use of protease inhibitors, since no cross-resistance exists between these two drug classes. More recently, newer NNRTI compounds that have somewhat distinct resistance profiles have also been developed to provide benefits to patients when these compounds are used as a part of a secondline regimen [13] .
In this context, the discovery of integrase strand transfer inhibitors (INSTIs) is important as a means of extending therapeutic options for individuals living with HIV. The integrase gene and enzyme of HIV were recognized early to be a potential therapeutic target and were shown to be susceptible to inhibition by oligonucleotides and synthetic peptides as early as 1995 [14, 15] . However, a seminal study only described the first promising small compound targeting integrase in 2000 [16] .
This, in turn, has led to the development of all currently approved integrase inhibitors.
In the USA, INSTIs currently available for HIV treatment include raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG).
Integration is a two-step reaction catalyzed by the HIV integrase protein (reviewed in [17, 18] ). The first step consists of the processing of the 3 0 end of the newly retrotranscribed double-stranded viral DNA and is followed by the strand transfer reaction that results in the irreversible insertion of the viral genome into the host DNA. RAL, EVG, and DTG specifically inhibit the strand transfer step of integration [16, 19] . INSTIs have demonstrated long-term safety and efficacy [20] [21] [22] [23] [24] for the treatment of individuals living with multiple HIV subtypes [25] [26] [27] . Here, we review the use of INSTIs in first-and second-line HIV treatment regimens, as well as the potential to use these drugs sequentially after treatment failure as well as the issue of resistance.
METHODS
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
Clinical studies reviewed in this manuscript were deemed important to the field of HIV integrase inhibitors by the authors. Most of these studies included large cohorts of patients.
We also searched PubMed using the terms ''raltegravir'', ''elvitegravir'', and ''dolutegravir'' as well as both the previous and brand names for these drugs. 
INTEGRASE INHIBITORS FOR FIRST-AND SECOND-LINE TREATMENT

SEQUENTIAL STRATEGY FOR THE USE OF INTEGRASE INHIBITORS AND THE ISSUE OF RESISTANCE
The concept of sequential strategy in regard to integrase inhibitors has not been fully explored.
Although little information is available on this subject, the following facts are well-known.
First, it is unlikely that RAL and EVG will ever RAL raltegravir, TDF tenofovir disoproxil fumarate, FTC emtricitabine, EFV efavirenz, EVG/c cobicistat-boosted elvitegravir, ATV/r ritonavir-boosted atazanavir, ABC abacavir, 3TC lamivudine, DTG dolutegravir, PI protease inhibitor, LPV/r ritonavir-boosted lopinavir be able to be used sequentially in therapy, since the resistance profiles of these two compounds overlap to considerable extent [5, 6] . The only possibility for use of these compounds in sequential fashion might be if a change in therapy is contemplated at a time that resistance has not yet developed against either of these agents. The rationale for such a substitution could include the fact that RAL is a twice-daily drug and that some patients might prefer to be on the once-daily regimen of coformulated EVG/c/TDF/FTC. In contrast, there are some patients who cannot take a pharmacological booster such as cobicistat for reasons of drug interactions and who might need instead to take the twice-daily regimen of RAL, complemented by two members of the nucleoside family of drugs [70] . The use of DTG to rescue patients who have first developed resistance to RAL has also been studied and documented [71] . In almost all cases, it appears as though some measure of patient benefit can be obtained if DTG is used to treat individuals who have developed resistance to either RAL or EVG, after the development of mutations in the integrase gene that follow one of the well-described resistance pathways for these compounds.
However, it should also be noted that DTG 
SHOULD DTG BE USED AS A FIRST-LINE DRUG?
The danger of delaying the use of DTG is that significant numbers of individuals who develop resistance to RAL and/or EVG may, by that time, have lost their ability to respond in fully efficacious fashion to DTG. For example, the results of the VIKING studies raise the issue of durability of responsiveness to a DTG-based regimen in second-line therapy after relevant INSTI mutations for RAL and EVG are already in place.
Further information on this topic is provided by the results of the SAILING study that evaluated the use of RAL vs. DTG in a context in which previously treatment-experienced patients had received therapy with many other types of drugs but not with INSTIs. Moreover, the patients in this trial had developed resistance against many of the compounds that were used [46] . This is important, as it suggests that DTG is a more potent compound than RAL when either of these drugs is used in a salvage setting for patients who have previously failed traditional drug regimens that did not include an INSTI. At the same time, patients in the RAL arm of the trial who developed resistance against the latter compound did so due to development of mutations that are associated with the latter drug. In contrast, patients in the DTG arm of the trial developed resistance in very few cases. Two individuals developed the R263K mutation [72] that had earlier been shown to be of potential significance for DTG on the basis of tissue culture selection studies [73] . Accordingly, it appears that resistance to DTG in the clinic may be very 
